info:eu-repo/semantics/article
Progress in progestin-based therapies for neurological disorders
Fecha
2021-03Registro en:
Sitruk-Ware, Regine; Bonsack, Brooke; Brinton, Roberta; Schumacher, Michael; Kumar, Narender; et al.; Progress in progestin-based therapies for neurological disorders; Pergamon-Elsevier Science Ltd; Neuroscience and Biobehavioral Reviews; 122; 3-2021; 38-65
0149-7634
CONICET Digital
CONICET
Autor
Sitruk-Ware, Regine
Bonsack, Brooke
Brinton, Roberta
Schumacher, Michael
Kumar, Narender
Lee, Jea Young
Castelli, Vanessa
Corey, Sydney
Coats, Alexandreya
Sadanandan, Nadia
Gonzales Portillo, Bella
Heyck, Matt
Shear, Alex
Blaise, Cozene
Zhang, Henry
Sheyner, Michael
García Sánchez, Julián
Navarro, Lisset
El Etr, Martine
de Nicola, Alejandro Federico
Borlongan, Cesar V.
Resumen
Hormone therapy, primarily progesterone and progestins, for central nervous system (CNS) disorders represents an emerging field of regenerative medicine. Following a failed clinical trial of progesterone for traumatic brain injury treatment, attention has shifted to the progestin Nestorone for its ability to potently and selectively transactivate progesterone receptors at relatively low doses, resulting in robust neurogenetic, remyelinating, and anti-inflammatory effects. That CNS disorders, including multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), spinal cord injury (SCI), and stroke, develop via demyelinating, cell death, and/or inflammatory pathological pathways advances Nestorone as an auspicious candidate for these disorders. Here, we assess the scientific and clinical progress over decades of research into progesterone, progestins, and Nestorone as neuroprotective agents in MS, ALS, SCI, and stroke. We also offer recommendations for optimizing timing, dosage, and route of the drug regimen, and identifying candidate patient populations, in advancing Nestorone to the clinic.